Intellipharmaceutics International Inc. (IPCI)

[Tekterra]

You have to get the words out there is now this new version of generics. Then you're looking at competing with others, and you're trying to get customers to buy your version.

There has to be a selling point. If IPCI version has no advantage and it's just the same like another generic, then you're looking at cutting the price to compete by selling lower in bulks. That cuts into your profit.

Relying on sales force to call direct and trying to sell it might take a while if you don't do some kind of promotional adds.

So when you add all your cost up from producing the pills to packaging, transporting and any other cost in marketing you would have a good idea if you turn profit or not.

If I was a buyer, I'd think about all my options of generics and which one cost less as well as any advantages of that particular version of the drug? If they are all the same, then all I really care about is who sells lower.

There is typically a good business relationship between a sales rep and a customer. And for the customer to suddenly switch to buying from someone else, there has to be a good reason for that customer. so then the question is what does IPCI has to offer?

We don't currently have the overdose prevention tech yet. That still something of an unproven concept. If overdose prevention was actually developed, that would be a different story. Getting a partner for Glucophage would be a tough one. I think IPCI missed opportunities in the last 4 years, and it becomes increasingly difficult to gain market now compares to years ago.